ImevaX

About:

ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany

Twitter/X: imevax

Top Investors: Wellington Partners, German Federal Ministry of Education and Research, BioMedPartners, Santo Venture Capital, EMBL Ventures

Description:

ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard and his team discovered that the colonization ability (and hence, the infectiousness) of H. pylori depends on a secreted bacterial factor that down-regulates the host immune system. Many other highly infectious pathogens have evolved similar immune evasion mechanisms, which are the focus of the ImevaX screening program.

Total Funding Amount:

13.4M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Munich, Bayern, Germany

Founded Date:

2014-01-01

Contact Email:

info(AT)ImevaX.com

Founders:

Markus Gerhard

Number of Employees:

11-50

Last Funding Date:

2015-03-02

IPO Status:

Private

Industries: